Ru­bius lands $120M bo­nan­za to fund a ground­break­ing pipeline ef­fort on a new drug plat­form

The peo­ple at Ru­bius Ther­a­peu­tics think they’re on to a game-chang­ing new plat­form for drug R&D, one that can spawn a wave of trans­for­ma­tion­al new med­i­cines. And they now have one of the biggest ven­ture cap­i­tal rounds in drug R&D this year to put their dreams to the test in a line­up of new pro­grams now head­ed for the clin­ic.

Seed­ed by Flag­ship Pi­o­neer­ing and ini­tial­ly backed with a $25 mil­lion A round in late 2015, Ru­bius to­day is un­cork­ing a $120 mil­lion in­vest­ment “to move a wave of prod­ucts in­to the clin­ic next year,” says Ru­bius Pres­i­dent Tor­ben Straight Nis­sen. Af­ter dou­bling the staff to 40 over the last 9 months, Ru­bius will now shoot for 100 over the next year.

Tak­ing a page from Mod­er­na — a Flag­ship start­up that at­tract­ed hun­dreds of mil­lions of dol­lars ear­ly on to fi­nance an­oth­er shot at a close­ly-watched break­through ef­fort — Ru­bius isn’t look­ing to prove what they can do with just one or two pro­grams. The team wants to lay out a full pipeline, prefer­ably with a cou­ple of ma­jor league part­ners com­ing in ear­ly to help lever­age the kind of fi­nan­cial fire­pow­er need­ed to ex­e­cute on what they be­lieve is a game-chang­er in biotech.

“We’re mov­ing for­ward on dif­fer­ent in­di­ca­tions and dif­fer­ent fea­tures that test the tech­nol­o­gy,” Straight Nis­sen tells me. The most ad­vanced are en­zyme re­place­ments ther­a­pies and new treat­ments for sol­id tu­mors and hema­to­log­i­cal ma­lig­nan­cies.

“We’ve pro­ject­ed that we’ll be in the clin­ic in 2018,” he says, adding that that is as spe­cif­ic as he wants to get on that top­ic right now.

The red-cell ther­a­py tech they have is de­signed to iso­late hematopoi­et­ic stem cells from O neg­a­tive donors and use them as the build­ing blocks for new ther­a­pies, ge­net­i­cal­ly en­gi­neer­ing them in­to red blood drugs that can ex­press a mul­ti­tude of pro­teins on the cells while they still have a nu­cle­us, mod­u­lat­ing them for pro­tein ex­pres­sion and then shed­ding the nu­cle­us as they switch on the ther­a­peu­tic qual­i­ties of the cell.

Es­sen­tial­ly, it’s a sci­en­tif­ic hi­jack­ing, tak­ing cells and turn­ing them in­to a new fleet of ther­a­pies.

David Ep­stein

The key chal­lenge right now, says Straight Nis­sen, is pick­ing the first wave for the pipeline from a large num­ber of po­ten­tial tar­gets. But this kind of al­lo­gene­ic ap­proach sug­gests a va­ri­ety of av­enues, in­clud­ing find­ing a new way to de­vel­op an off-the-shelf mech­a­nism to re­cruit a T cell at­tack on can­cer cells, hit­ting the tu­mor mi­croen­vi­ron­ment — ground ze­ro in the can­cer field — in a way that avoids un­con­trolled ex­pan­sion of T cells with po­ten­tial­ly cat­a­stroph­ic re­ac­tions.

Noubar Afeyan

Ru­bius in many ways rep­re­sents the kind of biotech gam­ble that Flag­ship wants to be­come known for. It draws on some in­spi­ra­tion from a mar­quee sci­en­tist — in this case MIT’s Har­vey Lodish — while build­ing on the tech­nol­o­gy in their Flag­ship Ven­ture­Labs and em­ploy­ing a big team led by in­dus­try pro­fes­sion­als to prove it works. In this case lead­ers in­clude Straight Nis­sen, who joined Ru­bius from Pfiz­er, as well as No­var­tis vet­er­an David Ep­stein, a new ex­ec­u­tive part­ner at Flag­ship who is tak­ing on the chair­man’s role.

Flag­ship is pro­vid­ing the cash, along with some silent in­sti­tu­tion­al part­ners. And you can bet they’re talk­ing to some ma­jor play­ers to see who would like to col­lab­o­rate on the cause.

The biotech is “fol­low­ing in the foot­steps of Flag­ship’s fam­i­ly of suc­cess­ful mul­ti­prod­uct plat­form com­pa­nies,” says Flag­ship CEO and Ru­bius co-founder Noubar Afeyan. And they have the cash now to find out just how far that path might lead.

Med­ical an­i­ma­tion: Mak­ing it eas­i­er for the site and the pa­tient to un­der­stand

Medical animation has in recent years become an increasingly important tool for conveying niche information to a varied audience, particularly to those audiences without expertise in the specialist area. Science programmes today, for example, have moved from the piece-to-camera of the university professor explaining how a complex disease mechanism works, to actually showing the viewer first-hand what it might look like to shrink ourselves down to the size of an ant’s foot, and travel inside the human body to witness these processes in action. Effectively communicating a complex disease pathophysiology, or the novel mechanism of action of a new drug, can be complex. This is especially difficult when the audience domain knowledge is limited or non-existent. Medical animation can help with this communication challenge in several ways.
Improved accessibility to visualisation
Visualisation is a core component of our ability to understand a concept. Ask 10 people to visualise an apple, and each will come up with a slightly different image, some apples smaller than others, some more round, some with bites taken. Acceptable, you say, we can move on to the next part of the story. Now ask 10 people to visualise how HIV’s capsid protein gets arranged into the hexamers and pentamers that form the viral capsid that holds HIV’s genetic material. This request may pose a challenge even to someone with some virology knowledge, and it is that inability to effectively visualise what is going on that holds us back from fully understanding the rest of the story. So how does medical animation help us to overcome this visualisation challenge?

Alice Shaw, Lung Cancer Foundation of America

Top ALK ex­pert and can­cer drug re­searcher Al­ice Shaw bids adieu to acad­e­mia, hel­lo to No­var­tis

Jay Bradner has recruited a marquee oncology drug researcher into the ranks of the Novartis Institutes for BioMedical Research. Alice Shaw is jumping from prestigious posts intertwined through Mass General, Harvard and Dana-Farber to take the lead of NIBR’s translational clinical oncology group.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.

Christine Bunt, Robert Langer. Verseau

Armed with Langer tech and $50M, Verseau hails new check­point drugs un­leash­ing macrophages against can­cer

The rising popularity of CD47 has propelled the “don’t-eat-me” signal to household name status in the immuno-oncology world. But just as PD-(L)1 merely represents the most fruitful of all checkpoints regulating T cells, Verseau Therapeutics is convinced that CD47 is one of many regulators one can modulate to stir up or tame the immune system.

“Macrophages are interesting because we were all educated probably 20 years ago that they are the big eaters in the immune system, but they’re really the orchestrators of the immune system,” CEO Christine Bunt said.

Hal Barron, GSK's president of R&D and CSO, speaks to Endpoints News founder and editor John Carroll in London at Endpoints' #UKBIO19 summit on October 8, 2019

[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&D chief Hal Bar­ron talks about a new era at GSK

Last week I had a chance to sit down with Hal Barron at Endpoints’ #UKBIO19 summit to discuss his views on R&D at GSK, a topic that has been central to his life since he took the top research post close to 2 years ago. During the conversation, Barron talked about changing the culture at GSK, a move that involves several new approaches — one of which involves celebrating their setbacks as they shift resources to the most promising programs in the pipeline. Barron also discussed his new alliances in the Bay Area — including his collaboration pact with Lyell, which we covered here — frankly assesses the pluses and minuses of the UK drug development scene, and talks about his plans for making GSK a much more effective drug developer.

This is one discussion you won’t want to miss. Insider and Enterprise subscribers can log-in to watch the video.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Mi­rati preps its first look at their KRAS G12C con­tender, and they have to clear a high bar for suc­cess

If you’re a big KRAS G12C fan, mark your calendars for October 28 at 4:20 pm EDT.

That’s when Mirati $MRTX will unveil its first peek at the early clinical data available on MRTX849 in presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

Mirati has been experiencing the full effect of a rival’s initial success at targeting the G12C pocket found on KRAS, offering the biotech some support on the concept they’re after — and biotech fans a race to the top. Amgen made a big splash with its first positive snapshot on lung cancer, but deflated sky-high expectations as it proved harder to find similar benefits in other types of cancers.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.

The FDA will hus­tle up an ex­pe­dit­ed re­view for As­traZeneca’s next shot at a block­buster can­cer drug fran­chise

AstraZeneca paid a hefty price to partner with Daiichi Sankyo on their experimental antibody drug conjugate for HER2 positive breast cancer. And they’ve been rewarded with a fast ride through the FDA, with a straight shot at creating another blockbuster oncology franchise.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.

Sean Parker, AP

Sean Park­er helps cre­ate a CRISPRed cell ther­a­py 2.0 play — and he’s got a high-pro­file set of lead­ers on the team

You can rack up one more high-profile debut effort in the wave of activity forming around cell therapy 2.0. It’s another appealing Bay Area group that’s attracted some of the top hands in the business to a multi-year effort to create a breakthrough. And they have $85 million in hand to make that first big step to the clinic.

Today it’s Ken Drazan and the team at South San Francisco-based ArsenalBio that are coming from behind the curtain for a public bow, backed by billionaire Sean Parker and a collection of investors that includes Beth Seidenberg’s new venture investment operation based in LA.
Drazan — a J&J Innovation vet with a long record of entrepreneurial endeavors — exited the stage in 2018 when his last mission ended as he stepped aside as president of Grail. It wasn’t long, though, before he was helping out with a business plan for ArsenalBio that revolved around the work of a large group of interconnected scientists supported by the Parker Institute for Cancer Immunology.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.

CSL ac­cus­es ri­val Pharm­ing of par­tic­i­pat­ing in a scheme to rip off IP on HAE while re­cruit­ing se­nior R&D staffer

Pharming has landed in the middle of a legal donnybrook after recruiting a senior executive from a rival R&D team at CSL. The Australian pharma giant slapped Pharming with a lawsuit alleging that the Dutch biotech’s new employee, Joseph Chiao, looted a large cache of proprietary documents as he hit the exit. And they want it all back.
Federal Judge Juan Sanchez in the Eastern District Pennsylvania court issued an injunction on Tuesday prohibiting Chiao from doing any work on HAE or primary immune deficiency in his new job and demanding that he return any material from CSL that he may have in his possession. And he wants Pharming to tell its employees not to ask for any information on the forbidden topics.
For its part, Pharming fired off an indignant response this morning denying any involvement in extracting any kind of IP from CSL, adding that it’s cooperating in the internal probe that CSL has underway.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.

Eli Lil­ly’s first PhI­II show­down for their $1.6B can­cer drug just flopped — what now?

When Eli Lilly plunked down $1.6 billion in cash to acquire Armo Biosciences a little more than a year ago, the stars seemed aligned in its favor. The jewel in the crown they were buying was pegilodecakin, which had cleared the proof-of-concept stage and was already in a Phase III trial for pancreatic cancer.

And that study just failed.

Lilly reported this morning that their cancer drug flopped on overall survival when added to FOLFOX (folinic acid, 5-FU, oxaliplatin), compared to FOLFOX alone among patients suffering from advanced pancreatic cancer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.